/
BOLD
$2.78-$0.00 (-0.18%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$63.2M
23M shares
52-week range
$0.96 – $2.97
90% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-11.47
Boundless Bio, Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
www.boundlessbio.com- Employees
- 28
- IPO / List date
- Mar 28, 2024
- HQ
- LA JOLLA, CA
Held by traders on TradeandTell
No one on the platform currently holds BOLD.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 399,000 | $438.9K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BOLD yet.
